Despite a lack of scientific studies on its efficacy for Covid-19, interest in the treatment has surged alongside case numbers. In August, the Food and Drug Administration broadened its emergency use authorization (EUA) for convalescent plasma, which uses the antibodies in recovered Covid-19 patients’ blood to treat those still suffering from the disease. In a …
The post Blood Facilities Are Barely Assembly Convalescent Plasma Demand appeared first on iTechBlog.
Source: https://ift.tt/35pHpGT
Không có nhận xét nào:
Đăng nhận xét